Will a Cardene (nicardipine) drip lower heart rate in an adult patient with a history of cardiovascular disease or hypertension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Will Cardene (Nicardipine) Drip Lower Heart Rate?

No, Cardene (nicardipine) drip will not lower heart rate—it typically increases heart rate as a reflex response to vasodilation and blood pressure reduction. 1

Mechanism and Hemodynamic Effects

Nicardipine is a dihydropyridine calcium channel blocker that works by selectively relaxing vascular smooth muscle, producing significant decreases in systemic vascular resistance without directly affecting cardiac conduction or contractility 1. The drug's effects are more selective to vascular smooth muscle than cardiac muscle 1.

The increase in heart rate is a normal physiological response to vasodilation and decreased blood pressure 1. When nicardipine causes peripheral vasodilation and blood pressure drops, the body's baroreceptor reflex triggers compensatory tachycardia to maintain cardiac output 2.

Expected Heart Rate Changes

In placebo-controlled trials, nicardipine produced mean heart rate increases of:

  • 7 ± 1 bpm in postoperative patients 1
  • 8 ± 1 bpm in patients with severe hypertension 1

While nicardipine may increase heart rate acutely, some studies suggest that tachycardia does not persist during long-term oral therapy 2. However, for IV infusions used in acute settings, the reflex tachycardia remains a consistent finding 3.

Clinical Implications for Cardiovascular Patients

In Coronary Artery Disease

In patients with coronary disease, it is prudent to avoid tachycardia when lowering blood pressure 4. The European Society of Cardiology guidelines emphasize that blood pressure should be lowered gradually in coronary patients and tachycardia should be avoided 4.

Nicardipine's tendency to increase heart rate may be problematic in patients with:

  • Active coronary ischemia (increased myocardial oxygen demand) 4
  • Recent myocardial infarction 4
  • Unstable angina 4

Combination with Beta-Blockers

The combined use of nicardipine with beta-blockers may be beneficial, as beta-blockers can prevent the reflex tachycardia induced by nicardipine's vasodilation, while nicardipine prevents the increase in peripheral vascular resistance that occurs during beta blockade 2.

Electrophysiologic Properties

Nicardipine has no negative effect on cardiac conduction at therapeutic doses 1. During acute electrophysiologic studies, nicardipine:

  • Increased heart rate 1
  • Prolonged the corrected QT interval to a minor degree 1
  • Did not affect sinus node recovery or SA conduction times 1
  • Did not prolong AV nodal conduction time 1

This distinguishes nicardipine from non-dihydropyridine calcium channel blockers (verapamil, diltiazem), which do slow heart rate and can cause bradyarrhythmias 4.

Practical Considerations

When Heart Rate Control is Needed

If heart rate reduction is a therapeutic goal (such as in atrial fibrillation, supraventricular tachycardia, or acute coronary syndromes), nicardipine is not the appropriate agent 4. Instead, consider:

  • Beta-blockers (esmolol for acute IV control) 4
  • Non-dihydropyridine calcium channel blockers (diltiazem or verapamil) 4

Monitoring During Nicardipine Infusion

Continuous heart rate monitoring is essential during nicardipine infusion 5, 6. Watch for:

  • Pronounced tachycardia (some patients may develop marked increases) 1
  • Signs of myocardial ischemia if heart rate increases significantly in patients with coronary disease 5
  • Palpitations (a commonly reported adverse effect) 4

Special Populations

In patients with heart failure and preserved systolic function, nicardipine increased cardiac output and improved left ventricular function, but the heart rate increase was still observed 7. The drug should be used with caution in patients with severe left ventricular dysfunction, as it may have a negative inotropic effect 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment for New Hypertension in the Emergency Room

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Hypertensive Urgency in Post-PCI Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

Does Cardizem (Diltiazem) cause tachycardia?
Can nicardipine be used to treat a patient with congestion?
What is the best course of action to manage hypertension in a patient on a nicardipine drip with a blood pressure of 163/80 mmHg?
Can Cardene (nicardipine) cause reflex tachycardia?
Is nicardipine (calcium channel blocker) indicated for a patient with hypertension (elevated blood pressure) and epigastric pain?
Why is enzalutamide (an androgen receptor inhibitor) not considered a first-line treatment for a patient with high-volume metastatic hormone-sensitive prostate cancer, when androgen deprivation therapy (ADT) plus docetaxel (a chemotherapy agent) plus abiraterone (an androgen receptor inhibitor) or darolutamide (an androgen receptor inhibitor) are recommended as first-line treatments?
What is the recommended treatment for a patient with high-volume metastatic hormone-sensitive prostate cancer, considering options like Abiraterone (abiraterone) and Darolutamide (darolutamide) in terms of overall survival benefits?
What are the symptoms and treatment options for a patient with suspected gut parasite infection, particularly those with a history of travel or exposure to contaminated food and water?
Should Abiraterone acetate (abiraterone) be taken with food or on an empty stomach for optimal absorption in a patient with prostate cancer?
How do you choose between abiraterone (Zytiga) and darolutamide (Nubeqa) for a patient with high-volume metastatic hormone-sensitive prostate cancer, given the differences in trial design and evaluation points?
What is the appropriate management for a patient presenting with renal contour distortion with prominence, potentially indicating renal tumors, obstructive uropathy, or polycystic kidney disease?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.